Loading…
2 companies · GEL, thousands · columns ordered by revenue
| Ratio — FY 2024 | Abulpharm | Shotapharm |
|---|---|---|
| Margins | ||
| Gross Margin | 52.6% | 49.6% |
| EBITDA Margin | 52.7% | 47.9% |
| EBITDAR | 179,946 | 156,914 |
| EBITDAR Margin | 52.7% | 47.9% |
| EBIT Margin | 52.7% | 47.9% |
| Net Profit Margin | 52.7% | 47.9% |
| Operating Expense % of Sales | 2.0% | 1.7% |
| Returns | ||
| Return on Assets (ROA) | 48.3% | 45.2% |
| Return on Equity (ROE) | 75.8% | 74.0% |
| ROIC [EBIT / Invested Capital] | 78.8% | 77.2% |
| Leverage & debt balances | ||
| Debt-to-Assets | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x |
| Equity-to-Assets | 63.7% | 61.0% |
| Net Debt | -9,029 | -8,614 |
| Cash & Equivalents | 9,029 | 8,614 |
| Total Debt | N/A | N/A |
| Liquidity & working capital | ||
| Current Ratio | 2.75x | 2.56x |
| Quick Ratio | 2.72x | 2.51x |
| Cash Ratio | 0.07x | 0.06x |
| Total Current Assets | 372,077 | 347,147 |
| Total Current Liabilities | 135,495 | 135,425 |
| Inventory | 3,180 | 7,354 |
| Trade Receivables | 359,868 | 331,449 |
| Trade Payables | 135,223 | 135,425 |
| Net Working Capital | 236,582 | 211,722 |
| Net Working Capital % of Revenue | 69.3% | 64.7% |
| Trade Working Capital | 227,825 | 203,378 |
| Trade Working Capital % of Revenue | 66.8% | 62.1% |
| Change in Trade Working Capital | N/A | N/A |
| Turnover & efficiency | ||
| Inventory Turnover | 50.82x | 22.43x |
| Days Inventory Outstanding (DIO) | 7.2 | 16.3 |
| Receivables Turnover | 0.95x | 0.99x |
| Days Sales Outstanding (DSO) | 384.9 | 369.5 |
| Payables Turnover | 1.20x | 1.22x |
| Days Payable Outstanding (DPO) | 305.4 | 299.7 |
| Cash Conversion Cycle | 86.7 days | 86.1 days |
| Asset Turnover | 0.92x | 0.94x |
| Cash flow & dividends | ||
| Operating Cash Flow | 431 | -973 |
| Free Cash Flow (OCF − Capex proxy) | -358 | -973 |
| Cash Conversion (OCF / EBITDA) | 0.2% | -0.6% |
| Dividends Declared | 90 | 87 |
| Dividend Payout Ratio | 0.1% | 0.1% |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Abulpharm | Pharma | 52.7% | 98th pct | 110 |
| Shotapharm | Pharma | 47.9% | 95th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.